生殖支原体的体外培养与抗菌药物敏感性检测面临的挑战
生殖支原体是性传播病原体,体外培养极为困难,导致表型药敏检测非常规开展,临床多依靠分子检测已知耐药决定因子来推断敏感性。然而耐药决定因子检测与临床治疗失败之间的关联并不总是明确,且分子方法难以发现新发耐药机制。本综述汇总了生殖支原体初始分离培养系统的发展及当前表型药敏检测方法,并指出与淋病奈瑟菌类似,未来治疗选择极为有限,表型药敏检测对评估潜在疗法具有重要价值。
要点
- 生殖支原体体外培养极为困难,表型药敏检测非常规开展。
- 一线大环内酯类和二线氟喹诺酮类耐药均有常见报道。
- 分子检测已知耐药决定因子与临床治疗失败关联并不总是明确。
核心结论
- 生殖支原体未来治疗选择极为有限,若要保持可治疗性,表型药敏检测在评估潜在疗法中将发挥重要作用,保留这些技术至关重要。
研究设计与样本
- 本文为综述,汇总并讨论生殖支原体初始分离培养系统的发展及当前用于表型药敏检测的方法学。
主要发现
- 生殖支原体体外培养极为困难,成功体外培养对许多研究者仍难以实现。
- 对一线推荐治疗(大环内酯类)和二线推荐治疗(氟喹诺酮类)的抗菌药物耐药均有常见报道。
- 由于体外生长困难,表型药敏检测非常规开展,转而采用分子检测已知耐药决定因子来推断敏感或耐药。
- 耐药决定因子检测与临床治疗失败之间的关联并不总是明确。
- 分子检测对新发耐药机制的检测用途有限。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The sexually transmitted bacterial pathogen Mycoplasma genitalium has proved a complex organism to work with in the laboratory setting. Exhibiting an extremely fastidious nature, successful in vitro propagation of M. genitalium has remained elusive for many researchers. Antimicrobial resistance to both first- and second-line recommended therapies (macrolides and fluoroquinolones, respectively) is commonly reported. However, phenotypic susceptibility testing is not routinely performed, due to the difficulties of in vitro growth. Instead, molecular detection of known resistance determinants is used to infer susceptibility/resistance. However, associations between determinant detection and clinical treatment failure are not always clear. Furthermore, molecular assays have limited use for detection of emerging resistance mechanisms. The present review collates and discusses the development of successful culture systems for initial isolation of this organism and current methodologies employed for phenotypic susceptibility testing to aid researchers in this field. As with Neisseria gonorrhoeae, future treatment options are extremely limited for M. genitalium and, if this sexually transmitted infection is to remain treatable, phenotypic susceptibility testing will play an invaluable role in evaluation of potential therapeutics. As such, retainment of these techniques is imperative.
引用
- Pitt R, Boampong D, Day M, et al. Challenges of in vitro propagation and antimicrobial susceptibility testing of Mycoplasma genitalium. J Antimicrob Chemother. 2022. PMID: 35979812. doi:10.1093/jac/dkac281
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。